

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

RAGWITEK
(short ragweed pollen allergen extract)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Ragwitek is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or *in vitro* testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in persons 5 through 65 years of age.

Ragwitek is not indicated for the immediate relief of allergic symptoms.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis

AND

- The diagnosis has been confirmed by positive skin test or *in vitro* testing for pollen-specific IgE antibodies for short ragweed pollen.

AND

- The patient does not have any of the following: A) Severe, unstable or uncontrolled asthma, B) History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy, C) History of eosinophilic esophagitis

AND

- The requested drug is being prescribed by, or in consultation with, an allergist or immunologist

REFERENCES

1. Ragwitek [package insert]. Hørsholm, Denmark: ALK-Abelló A/S.; April 2021.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed February 9, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed February 9, 2021.